Zydus Lifesciences LtdQ1 FY27
Zydus Lifesciences Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,096P/E: 22.9Market Cap: ₹1.1L CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →FY27 guidance: Strong double-digit overall revenue growth with mid-teens growth expected in India business.
- →India formulation business: 20% growth in branded portfolio; chronic therapies and innovation portfolios driving sustainable momentum.
- →International markets (EM and Europe): Continued strong growth with new market entries scaling faster than expected.
- →US business: Single-digit growth expected this year, with potential for double-digit growth in FY28 driven by pipeline and branded product scaling.
- →Consumer Wellness: Strong double-digit growth anticipated, continuing 25% like-to-like growth internationally.
- →Medical devices: Growth through investment in focused therapies and differentiation.
- →Medium term: Branded portfolio expected to exceed two-thirds of total revenue, driving improved growth and profitability.
- →Biosimilars: Already meaningfully scaled and profitable, contributing to growth.
- →Innovation assets, including Saroglitazar US launch (FY28) and specialty products, are key future growth drivers.
Margin guidance
Category 3- →Zydus Lifesciences projects strong double-digit revenue growth for FY27, with continued mid-teens growth in the India business and single-digit growth internationally.
- →EBITDA margin guidance is maintained at around 24% for FY27 despite increased investments in Saro and acquisitions.
- →Medium-term EBITDA margin target is 28-30% by FY30, driven by scaling up branded business to two-thirds of total revenues.
- →Mirabegron remains a profitable driver despite royalty costs, contributing positively to EBITDA.
- →Incremental Saro-related operating costs will increase in H2 FY27 but are factored into margin guidance.
- →Post-acquisition amortization impacts, like Mirabegron licensing, are expected to reduce by Q2 FY28.
- →Steady ramp-up of specialty, biosimilars, and 505(b)(2) portfolio to support profitability and margin expansion going forward.
3 more insights locked — sign up free to unlock
Fundraise plans
- →There is no specific mention on page 17 (or the surrounding pages) about any current or future plans for fundraising through debt or equity.
- →The company reported a net debt to EBITDA ratio of 0.7 times as of June 30, 2026, indicating manageable leverage.
- →CFO Mr. Tushar Shroff mentioned increased expenses mainly due to acquisitions, but no reference to new fundraising or debt issuances.
- →Overall, financial commentary focuses on operational performance, acquisitions, and margin guidance without disclosing any upcoming capital raising plans via debt or equity.
Order book
The transcript provided from the Zydus Lifesciences Q1 FY27 earnings call does not mention any details on the current or expected order book or pending orders. The discussion mainly covers topics such as:
- Aflibercept biosimilar launch in India and its positive initial traction.
- Business growth drivers including branded business share expanding to over two-thirds.
- US and international business performance, product launches, and margin guidance.
- Innovation pipeline, specialty products, acquisition impact, and margin outlook.
- No disclosures are made related to specific order book values or pending order quantities.
Therefore, no information is available in the document to provide current or expected order book or pending orders data for Zydus Lifesciences.
Capex plans
Yes- →Capex guidance for the full year is around ₹1,500-₹1,600 crores.
- →Investments include:
- → - Expansion of existing facilities: Moraiya, Goa, Baddi, Unit-2 and Unit-3 at SEZ.
- → - New formulation R&D center for development.
- → - One-time land acquisition for wellness business expansion.
- → - New CAR-T facility for biologics.
- → - New vaccines DS (Drug Substance) facility.
- → - Continued investment in Zylidac.
- →Saro (Saroglitazar US launch) will require investments primarily in FY27 and FY28, with build-out phase for first 2 years post-launch in FY28.
- →MedTech and specialty businesses are already invested and baked into current margin guidance.
- →Investments are spread across multiple areas to increase scale and capability, no single large capex item except wellness land acquisition.
How does Zydus Lifesciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Zydus Lifesciences Ltd
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Zydus Lifesciences Ltd rank in Pharmaceuticals & Biotechnology?
Compare Zydus Lifesciences Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.